The lancet oncology
The most recent articles from:
Lancet Oncol.
-
The lancet oncology · Nov 2014
Randomized Controlled Trial Multicenter StudyDacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical and clinical evidence of activity in non-small-cell lung cancer. We designed BR.26 to assess whether dacomitinib improved overall survival in heavily pretreated patients with this disease. ⋯ Canadian Cancer Society Research Institute and Pfizer.